Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review

The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colit...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoropoulos, Ioannis, Thomas, Konstantinos, Christoforou, Panagiotis, Fanidi, Iliana, Papavdi, Maria, Kyriakou, Fani, Deutsch, Melanie, Pirounaki, Maria, Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045858/
https://www.ncbi.nlm.nih.gov/pubmed/32185360
http://dx.doi.org/10.31138/mjr.30.3.167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045858/
https://www.ncbi.nlm.nih.gov/pubmed/32185360
http://dx.doi.org/10.31138/mjr.30.3.167

Ejemplares similares